Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Adverse Business Impact

Aurobindo Pharma Adverse Business Impact

US FDA classified Aurobindo's subsidiary facility as OAI after an inspection. The company states no immediate financial impact but faces regulatory scrutiny.

Source

NSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Aurobindo Pharma Ltd: key numbers

Share price
₹1,644.80
Market cap
₹95,530 Cr
Revenue (annual)
₹33,653 Cr
Net profit (annual)
₹3,505 Cr
P/E (TTM)
24.2×Sector 46.1×
Promoter holding
51.88%+0.00% QoQ
FII holding
17.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Aurobindo Pharma Ltd

All →

Other adverse business impact announcements

All →